Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Leukemia, Myeloid, Acute 35Leukemia 30Precursor Cell Lymphoblastic Leukemia-Lymphoma 27Lymphoma 27Lymphoma, Non-Hodgkin 22Burkitt Lymphoma 21Lymphoma, Mantle-Cell 20Leukemia, Lymphocytic, Chronic, B-Cell 20Lymphoma, Large B-Cell, Diffuse 19Lymphoma, Follicular 19Neuroblastoma 18Myelodysplastic Syndromes 18Multiple Myeloma 18Lymphoma, Large-Cell, Immunoblastic 17Lymphoma, B-Cell, Marginal Zone 17Hodgkin Disease 15Astrocytoma 14Medulloblastoma 13Breast Neoplasms 13Recurrence 12Central Nervous System Neoplasms 12Sarcoma 11Myeloproliferative Disorders 10Leukemia, Myeloid, Chronic-Phase 10Ovarian Neoplasms 9Leukemia, Myeloid, Accelerated Phase 9Familial ependymoma 9Carcinoma, Ovarian Epithelial 9Blast Crisis 9Optic Nerve Glioma 8

Interventions

Everolimus 10lutetium Lu 177 dotatate 5Magnetic Resonance Spectroscopy 5pasireotide 4Specimen Handling 3Positron Emission Tomography Computed Tomography 3Fluorodeoxyglucose F18 3(177)Lu-DOTA-EB-TATE 3olaparib 2amino-acid, glucose, and electrolyte solution 2Temozolomide 2Nivolumab 2FAPI-46 2veliparib 1vandetanib 1trifluridine tipiracil drug combination 1toripalimab 1tislelizumab 1talazoparib 1surufatinib 1romidepsin 1peposertib 1pembrolizumab 1pelcitoclax 1pegfilgrastim 1fosbretabulin 1fludarabine phosphate 1exemestane 1decitabine and cedazuridine drug combination 1dactolisib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Neuroendocrine Tumors × Filgrastim × Clear all
NCT02943733 2022-09-23

Safety of TAS-102 in Combination With Temozolomide for Metastatic Pancreatic NETs

University of Wisconsin, Madison

Phase 1 Terminated
18 enrolled
EndocrineNET

Neoplasms, Neuroectodermal Tumors, Primitive, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡